Sažetak
Uvod/Cilj. Trudnoća komplikovana antifosfolipidnim sindromom udružena je sa povećanim perinatalnim morbiditetom i mortalitetom. Cilj rada bio je procena perinatalnog ishoda u trudnoći sa primarnim antifosfolipidnim sindromom. Metode. U prospektivnoj studiji analizirali smo perinatalni ishod kod 25 trudnoća sa antifosfolipidnim sindromom. Po utvrđivanju vitalnosti trudnoće sve ispitivane bolesnice dobijale su niskomolekularni heparin i aspirin. Procena perinatalnog ishoda bazirana je na učestalosti pobačaja, prevremenih porođaja, živorođenosti i neonatalnih komplikacija. Rezultati. Ishod 25 analiziranih trudnoća bio je sledeći: 20 (80%) živorođenih, 3 (12%) spontana pobačaja i 2 (8%) mrtvorođenih. Prosečna gestacijska starost na rođenju iznosila je 37,2 ± 1,0 nedelja, a prosečna telesna masa novorođenčadi 2 930,4 ± 428,0 g. Prevremeni porođaj registrovan je kod 4 (20%) živorođenih, bilo je 4 (20%) slučaja intrauterinog zastoja u rastu ploda sa prosečnom težinom na rođenju od 2 060 ± 210,6 g, a neonatalne komplikacija bile su prisutne kod 6 (30%) novorođenčadi. Nepovoljan perinatalni ishod bio je značajno povezan sa antikardiolipinskim IgG antitelima (p < 0,01) i razvojem hipertenzije tokom trudnoće (p < 0,01). Zaključak. Uprkos visokoj incidenciji nepovoljnog perinatalnog ishoda trudnoća sa antifosfolipidnim sindromom, rano započinjanje tretmana sa niskomolekularnim heparinom i aspirinom, uporedo sa intenzivnim nadzorom majke i fetusa, moglo bi biti udruženo sa relativno velikom verovatnoćom povoljnog perinatalnog ishoda.
Ključne reči
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Reference
Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346(10): 752−63.
Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierengeli S, et al. Antiphospholipid syndrome clinical research task force report. Lupus 2011; 20(2): 219−24.
Xiao J, Xiong J, Zhu F, He L. Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syn-drome. Exp Therap Med 2013; 5(1): 287−91.
Tincani A, Branch W, Levy RA, Piette JC, Carp H, Rai RS, et al. Treatment of pregnant patients with antiphospholipid syn-drome. Lupus 2003; 12(7): 524−9.
Empson M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002; 99(1): 135−44.
Branch DW, Kamashta MA. Antiphospholipid syndrome: obste-tric diagnosis, management and controversies. Obstet Gy-necol 2003; 101(6): 1333−44.
Tadej A. Antiphospholipid antibody syndrome. In: Elzouki AY, Harfi HA, Nazer H, William OH, Stapleton FB, Whitley RJ, editors. Textbook of clinical pediatrics. 2nd ed. Berlin: Sprin-ger; 2012. p. 1641−8.
Branch DW, Peaceman AM, Druzin M, Silver RK, El-Sayed Y, Silver RM, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 2000; 182(1 Pt 1): 122−7.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4(2): 295−306.
Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132(2): 171−96.
Costa SL, Proctor L, Dodd JM, Toal M, Okun N, Johnson JA, et al. Screening for placental insufficiency in high-risk pregnancies: is earlier better? Placenta 2008; 29(12): 1034−40.
Durutović-Gligorović S. Antropometric normative for newborns Belgrade: Faculty of Medicine University of Belgrade; 2000. (Serbian)
Ruffati A, Tonnelo M, Cavazzana A, Bagatella P, Pengo V. Labora-tory classification and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 2009; 123(3): 482−7.
Serrano F, Nogueira I, Borges A, Branco J. Primary antiphopsholi-pid syndrome: pregnancy outcome in a portugese population. Acta Reumatol Port 2009; 34(3): 492−7.
Lockshin MD. Pregnancy and Antiphospholipid Syndrome. Am J Reprod Immunol 2012. doi: 10.1111/aji.12071. (In Press)
Di Prima F, Valenti O, Hyseni E, Giorgio E, Faraci M, Renda E, et al. Antiphospholipid syndrome during pregnancy: the state of art. J Prenatal Med 2011; 5(2): 41−53.